Fibroblast growth factor 23 and cause-specific mortality in the general population: The northern Manhattan study

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 10, 2016, Pages 3779-3786

  Souma, Nao ^a,b   Isakova, Tamara ^a,b   Lipiszko, David ^a,b   Sacco, Ralph L ^c,d,e   Elkind, Mitchell S V ^d,g   DeRosa, Janet T ^d   Silverberg, Shonni J ^f   Mendez, Armando J ^d   Dong, Chuanhui ^c   Wright, Clinton B ^c,d,e   Wolf, Myles ^a,b  

^a Institute for Public Health and Medicine   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Evelyn F McKnight Brain Institute   (United States)

^d Department of Neurology ^*  (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f New York Presbyterian Columbia University Medical Center   (United States)

^g Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CAUSE OF DEATH; CAUSE SPECIFIC MORTALITY; COHORT ANALYSIS; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RISK; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UPREGULATION; URBAN POPULATION; VASCULAR DISEASE; BLACK PERSON; BLOOD; CAUCASIAN; ETHNOLOGY; MIDDLE AGED; NEOPLASM; NEW YORK; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEW YORK CITY; RISK FACTORS; URBAN POPULATION; VASCULAR DISEASES;

EID: 84991628493     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2215     Document Type: Article

References (40)

1. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21(9):1427-1435.
2. Hasegawa H, Nagano N, Urakawa I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int. 2010;78(10):975-980.
3. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90(3):1519-1524.
4. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006;91(8):3144-3149.
5. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005;16(7):2205-2215.
6. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370-1378.
7. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584-592.
8. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risksofmortality and end-stagerenal diseaseinpatients with chronic kidney disease. JAMA. 2011;305(23):2432-2439.
9. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010;152(10):640-648.
10. Wright CB, Dong C, Stark M, et al. Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). Neurology. 2014;82(19):1700-1706.
11. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121(11):4393-4408.
12. Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015;22(6):1020-1032.
13. Rossaint J, Oehmichen J, Van Aken H, et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest. 2016;126(3):962-974.
14. Singh S, Grabner A, Yanucil C, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease [published online July 22, 2016]. Kidney Int. doi: 10.1016/j.kint.2016.05.019.
15. Wolf M. Mineral (mal)adaptation to kidney disease-Young Investigator Award Address: American Society of Nephrology Kidney Week 2014. Clin J Am Soc Nephrol. 2015;10(10):1875-1885.
16. Ix JH, Katz R, Kestenbaum BR, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2012;60(3):200-207.
17. Lutsey PL, Alonso A, Selvin E, et al. Fibroblast growth factor-23 and incident coronary heart disease, heart failure, and cardiovascular mortality: the Atherosclerosis Risk in Communities study. J Am Heart Assoc. 2014;3:e000936.
18. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J. 2011;161(5):956-962.
19. Ärnlöv J, Carlsson AC, Sundström J, et al. Higher fibroblast growth factor-23 increases the riskofall-cause and cardiovascular mortality in the community. Kidney Int. 2013;83(1):160-166.
20. Westerberg PA, Tivesten Å, Karlsson MK, et al. Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs). BMC Nephrol. 2013;14:85.
21. Sacco RL, Boden-Albala B, Abel G, et al. Race-ethnic disparities in the impact of stroke risk factors: the northern Manhattan stroke study. Stroke. 2001;32(8):1725-1731.
22. Wallman KK, Hodgdon J. Race and ethnic standards for Federal statistics and administrative reporting. Stat Report. 1977;77-110: 450-454.
23. Gentry EM, Kalsbeek WD, Hogelin GC, et al. The behavioral risk factor surveys: II. Design, methods, and estimates from combined state data. Am J Prev Med. 1985;1(6):9-14.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D.A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
25. Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14: 1707-1723.
26. Brandenburg VM, Kleber ME, Vervloet MG, et al. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen Risk and Cardiovascular Health Study. Atherosclerosis. 2014;237(1): 53-59.
27. Kendrick J, Cheung AK, Kaufman JS, et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.J Am Soc Nephrol. 2011;22(10):1913-1922.
28. Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006; 444(7120):770-774.
29. Ulaganathan VK, Sperl B, Rapp UR, Ullrich A. Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site. Nature. 2015;528(7583):570-574.
30. Spinola M, Leoni V, Pignatiello C, et al. Functional FGFR4 Gly388Arg polymorphism predicts prognosis in lung adenocarcinoma patients. J Clin Oncol. 2005;23(29):7307-7311.
31. Seitzer N, Mayr T, Streit S, Ullrich A. A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res. 2010;70(2):802-812.
32. Cross DS, Ivacic LC, Stefanski EL, McCarty CA. Population based allele frequencies of disease associated polymorphisms in the Personalized Medicine Research Project. BMC Genet. 2010;11:51.
33. National Center for Biotechnology Information. The Single Nucleotide Polymorphism database, Short Genetic Variations. Reference SNP Cluster Report: rs351855. http://www.ncbi.nlm.nih.gov/projects/SNP/snp-ref.cgi?rs=351855. Accessed May 25, 2016.
34. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684-700.
35. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342-357.
36. Chonchol M, Greene T, Zhang Y, Hoofnagle AN, Cheung AK. Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study. J Am Soc Nephrol. 2016;27(1):227-237.
37. Bai X, Miao D, Xiao S, et al. CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders. J Clin Invest. 2016;126(2):667-680.
38. Bacchetta J, Sea JL, Chun RF, et al. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1, 25-dihydroxyvitamin D in human monocytes. J Bone Miner Res. 2013;28(1):46-55.
39. Scialla JJ, Astor BC, Isakova T, Xie H, Appel LJ, Wolf M. Mineral metabolites and CKD progression in African Americans. J Am Soc Nephrol. 2013;24(1):125-135.
40. Isakova T, Xie H, Barchi-Chung A, et al. Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol. 2012;7(5):820-828.